NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00210314,Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma,https://clinicaltrials.gov/study/NCT00210314,,COMPLETED,"Aim of the study is to establish in a prospective, randomized clinical trial the activity of primary chemotherapy containing high dose-methotrexate, alone or combined with high dose cytarabine, in patients with primary central nervous system lymphoma",NO,"Lymphoma, B Cell",DRUG: high dose methotrexate|DRUG: high dose cytarabine|RADIATION: radiotherapy,The main endpoint is the complete remission (CR) rate after chemotherapy,Overall response rate|Response duration (time to relapse or progression) for responder patients|Overall survival|Event-free survival|Meningeal relapse rate|Early and late neurotoxicity,,International Extranodal Lymphoma Study Group (IELSG),,ALL,"ADULT, OLDER_ADULT",PHASE2,79,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,IELSG20,2003-07,2007-09,2007-12,2005-09-21,,2015-03-30,"Oncology Institute of Southern Switzerland (IOSI), Bellinzona, 6500, Switzerland",
